Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Caidya, formerly known as dMed Biopharmaceutical, is a global clinical research organization (CRO) founded in 2021 and headquartered in Raleigh, North Carolina. The company specializes in advancing healthcare innovation and accelerating the development of new therapies by offering comprehensive clinical trial services, including regulatory strategy, clinical operations, biometrics, and quality management.
Since its inception, Caidya has demonstrated significant growth and attracted substantial investor interest. The company has successfully raised a total of $244.1 million across multiple funding rounds, with its most recent Series C-II round in July 2021 securing $50 million at a valuation of $1 billion. This rapid growth in valuation, from $28 million in 2016 to $1 billion in 2021, showcases the company's strong market position and potential.
While there is currently no official news regarding Caidya's IPO prospects, the company's impressive funding history and valuation growth may position it as an attractive candidate for going public in the future. However, it's important to note that any discussions about a potential IPO remain speculative at this time.
Factors that could influence Caidya's decision to pursue an IPO include market conditions in the healthcare and biotechnology sectors, the company's financial performance, and its strategic growth plans. As a key player in the clinical research industry, Caidya's future moves will likely be of interest to investors looking to diversify their portfolios with exposure to the healthcare sector.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While dMed Biopharmaceutical's IPO prospects remain uncertain, investors eager to explore opportunities in the biopharmaceutical sector don't have to wait. At Linqto, we offer members access to interests in promising private companies before they go public. Our platform provides the opportunity to invest in potential leaders in the biopharmaceutical industry, like dMed, with lower minimum investments than traditional private equity opportunities. This allows you to potentially benefit from the growth of innovative companies in the healthcare sector before they hit the public markets.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
